The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Hikma Pharmaceuticals USA Inc. (formerly West-Ward Pharmaceuticals) is initiating a drug recall of five (5) lots of Lorazepam Injection, USP 2mg/mL-1mL vial and one (1) lot Lorazepam Injection, USP 4mg/ml-1 ml vial.

Item Description	Potency	Unit of sale	NDC	Lot	Exp. Dates	Ship Dates
Lorazepam Injection, USP	2mg/ml	25 vials/ carton	0641- 6044-25	070084	07/2023	08/17/2020- 08/31/2020
Lorazepam Injection, USP	2mg/ml	25 vials/ carton	0641- 6044-25	070126	07/2023	09/21/2020- 10/12/2020
Lorazepam Injection, USP	2mg/ml	25 vials/ carton	0641- 6044-25	080091	08/2023	09/29/2020- 11/02/2020
Lorazepam Injection, USP	2mg/ml	25 vials/ carton	0641- 6044-25	080060	08/2023	10/05/2020- 12/01/2020
Lorcueµam Injection, USP- Novaplus	2mg/ml	26 vials/ carton	0641- 6048-25	070088	07/2023	09/21/2020- 01/25/2021
Lorazepam Injection, USP	4mg/ml	25 vials/ carton	0641- 6045-25	070096	07/2023	08/18/2020- 12/14/2020

Reason for Recall:

This recall is being conducted due to Out of Specification for Lorazepam total related compounds observed during retain testing.